Large text / Standard text
Trials information Trials Information
The first two human Phase II trials of AIMSPRO have been designed to test two potential aspects of the medication’s mechanism of action. The scleroderma (diffuse sclerosis) study (at the Royal Free Hospital, London) will examine the safety and tolerance of AIMSPRO as a general anti-inflammatory agent in the later phase of this disabling chronic rheumatological disorder. 20 patients will be randomised to receive either AIMSPRO or placebo under double-blind conditions, over a period of 6 months.
In a study of AIMSPRO as a potential treatment of bladder dysfunction in secondary progressive multiple sclerosis (at the Whittington hospital, London) the hypothesised ability of the medication to reduce sodium channel triggering voltages will be tested, using a double-blind “cross-over” design.
Colleagues wishing to discuss these, or other potential studies, are welcome to contact Dr. Bryan Youl, Clinical Director, via Daval or by phoning + 44 7793 526 096.
The first two human Phase II trials of AIMSPRO have been designed to test two potential aspects of the medication’s mechanism of action. The scleroderma (diffuse sclerosis) study (at the Royal Free Hospital, London) will examine the safety and tolerance of AIMSPRO as a general anti-inflammatory agent in the later phase of this disabling chronic rheumatological disorder. 20 patients will be randomised to receive either AIMSPRO or placebo under double-blind conditions, over a period of 6 months.
In a study of AIMSPRO as a potential treatment of bladder dysfunction in secondary progressive multiple sclerosis (at the Whittington hospital, London) the hypothesised ability of the medication to reduce sodium channel triggering voltages will be tested, using a double-blind “cross-over” design.
Colleagues wishing to discuss these, or other potential studies, are welcome to contact Dr. Bryan Youl, Clinical Director, via Daval or by phoning + 44 7793 526 096.
